NCT00795522已完成4 期
An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 51
- 主要终点
- Change from Baseline in the Short Form 12 (SF-12) Health Survey Questionnaire, mental, physical and total scores on treatment days 7, 14, 21, and 28.
研究概览
简要总结
This open-label study is being conducted to determine the effect of DL treatment for CIU on symptom and disease severity, quality of life, daytime functioning, and quality of sleep.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- •Subjects must be >= 18 years of age, of either sex and any race.
- •Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation). Women of childbearing potential should be counseled in the appropriate use of birth control while in this study. Women who are not currently sexually active must agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the study.
- •Subjects must be in general good health; i.e., they must be free of any clinically significant disease (other than CIU) that would interfere with study evaluations.
- •Subjects must understand and be able to adhere to the dosing and visit schedules, and agree to complete the questionnaires and to record symptom severity scores, medication times, concomitant medications, and adverse events accurately and consistently in a daily diary.
- •Subjects must have at least a 6-week history of CIU (pruritus and hives) prior to Visit 1 (Screening).
- •Subjects must have a pruritus score >= 2 and a hive score >= 1 at Visit
- •Subjects must be experiencing a current CIU flare of at least 3 weeks duration, with hives present at least 3 days per week, prior to Visit 1 (Screening).
- •Subjects must score the overall condition of CIU >= 2 at both Visit 1 (Screening) and Visit 2 (Baseline).
- •Subjects must have a total pruritus score of >= 14 for the sum of morning and evening (reflective) diary scores for the 3 days prior to Visit 2 (Baseline) plus the morning score on the day of Visit
- •Women of childbearing potential must have a negative urine pregnancy test at Visit 2 (Baseline).
排除标准
- •Women who are pregnant or nursing.
- •Subjects who have not observed the designated washout periods for any of the prohibited medications outlined.
- •Subjects with asthma requiring chronic use of inhaled or systemic corticosteroids.
- •Subjects with drug or food allergies that manifest as skin reactions.
- •Subjects with urticaria that is primarily due to physical urticaria or other known etiology.
- •Subjects with CIU unresponsive to antihistamines.
- •Subjects who have been hospitalized (including an emergency department visit) because of deterioration in their CIU within 3 months prior to Visit 1 (Screening).
- •Subjects with a history of hypersensitivity to desloratadine or any of its excipients.
- •Subjects previously randomized into this study.
- •Subjects who are staff personnel directly involved with the administration of this study.
- •Subjects who have any clinically significant metabolic, cardiovascular, immunologic, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the Investigator, may interfere with the study evaluations or affect subject safety.
- •Subjects with a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study.
- •Subjects with a history of noncompliance with medications or treatment protocols.
研究组 & 干预措施
Arm 1
Experimental
Desloratadine
干预措施: Desloratadine (Drug)
结局指标
主要结局
Change from Baseline in the Short Form 12 (SF-12) Health Survey Questionnaire, mental, physical and total scores on treatment days 7, 14, 21, and 28.
时间窗: treatment days 7, 14, 21, and 28
次要结局
- Change from Baseline in work/school attendance and self-assessed productivity as measured by the WPAI questionnaire(treatment days 7, 14, 21, and 28)
- Change from Baseline in pruritus, the number of hives and the maximum size of hives, sleep quality, and activity impairment(treatment weeks 1, 2, 3, and 4)
- The percent of subjects who rate their response to therapy as either Complete, Marked, or Moderate Relief(day 28)
研究者
相似试验
已完成
3 期
How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)UrticariaNCT00795158Organon and Co282
已完成
4 期
Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)Rhinitis, Allergic, SeasonalNCT00805584Organon and Co311
已完成
不适用
Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)RhinitisNCT00704769Organon and Co591
Unknown
不适用
Role of Desloratadine in Reducing Inflammation From Occupational Heat StrainHeat Stress, ExertionalInflammatory ResponseFirefighter Personal Protective EquipmentNCT05446480University of Victoria12
已完成
2 期
Safety and Antidepressant Effects of Rellidep in Major Depressive DisorderDepressionNCT00446719Mount Sinai Hospital, Canada23